Welcome to SBS 2011 - SLAS

Gaylord Palms Resort and Convention Center | March 27–31, 2011 | Orlando, Florida, USA
9:00 am – 12:00 pm Osceola C
9:00 – 9:30 am Page 76
9:30 – 10:00 am Page 76
10:30 – 11:00 am Page 76
11:00 – 11:30 am Page 77
11:30 am – 12:00 pm Page 77
9:00 am – 12:00 pm Osceola B
9:00 – 9:30 am Page 79
9:30 – 10:00 am Page 79
10:30 – 11:00 am Page 79
11:00 – 11:30 am Page 80
11:30 am – 12:00 pm Page 80
Track II » Session 5: Leveraging a National Resource:
The Molecular Libraries Probe Development Network
(MLPCN)
Session Chair: Christopher Austin, NIH Chemical Genomics Center
Plenary: The MLPCN: Mission, Collaborative Operation, and
Accomplishments; Christopher Austin, NIH Chemical Genomics Center
High Content Screening: A Platform to Discover Novel Drug-Like &
Chemical Biological Probes for Several Target Classes; Thomas “T.C.” Chung,
Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical
Research Institute
Infectious Agents and Drug Discovery: How to Conduct HTS Screening
Campaigns Under BSL-2 and BSL-3 Level Containment; E. Lucile White,
Southern Research Specialized Biocontainment Screening Center
Integrating Novel Technologies to Identify Small-molecules that Drive
Translational Research and Therapeutics; Michelle Palmer, Broad Institute
of Harvard and MIT
Change in Heartbeat: When Vast Chemical Diversity Meets Ion Channel
Targets; Min Li, Johns Hopkins Ion Channel Center
Track III » Session 5: Prediction and Elucidation
of Target Liabilities
Session Chair: Keith Houck, Environmental Protection Agency
Plenary: Elucidation of Adverse Bioactivity Profiles as Predictors of Toxicity
Potential; Keith Houck, Environmental Protection Agency
Utilities of In Vitro Safety Pharmacology in Early Drug Discovery: Mitigation
of ADRs; Laszlo Urban, Novartis Institutes for Biomedical Research
From Data to Knowledge: Integration of Compound Structure and Activity
With Clinical ADRs; Eugen Lounkine, Novartis Institutes for Biomedical Research
Identification of Systemic Toxicity Triggers Associated With VEGF-R
Inhibitors; Paul Nioi, Amgen Inc.
In Silico Modeling for Predicting In Vivo Kinetics and Toxicity During Drug
Discovery; Simon Thomas, Cyprotex Discovery Ltd
Join the SLAS Social Media Communities
Our online communities are growing every day. Stay up-to-date
and join in the discussions. Sign-up now!
SLAS.org/events/sbs11 | 35